Our study demonstrated that the tumour burden can be used as a clinical biomarker for the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy, thereby providing valuable clinical implications for patients being administered this therapy. This evidence concerns the gene CD274 and neoplasm.